Skip to Content

Katerzia Approval History

FDA Approved: Yes (First approved July 8, 2019)
Brand name: Katerzia
Generic name: amlodipine benzoate
Dosage form: Oral Suspension
Company: Azurity Pharmaceuticals
Treatment for: High Blood Pressure, Coronary Artery Disease

Katerzia (amlodipine benzoate) is a calcium channel blocker in an oral suspension formulation indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, and coronary artery disease in adults.

Development History and FDA Approval Process for Katerzia

Jul 10, 2019Approval FDA Approves Katerzia (amlodipine) Oral Suspension for Pediatric Patients 6 Years of Age and Older

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.